Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.65 |
| ▸ | MAOA | P21397 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518907 | 0.86 | ESR1 (0.52) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL31668680 | 0.84 | MAOB (0.88) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL4526884 | 0.83 | MAOB (0.65) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL1576877 | 0.83 | NPC1 (0.63) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL9540720 | 0.83 | F2 (0.57) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL30026512 | 0.83 | NPC1 (0.63) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22803696 | 0.79 | NPC1 (0.67) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL4347943 | 0.77 | NPC1 (0.69) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL31668688 | 0.77 | MAOA (0.66) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL5177372 | 0.76 | MAOB (0.83) | MAOBMAOANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-111253336-B | Compounds for the treatment of cancer | GTX公司 | 2023-11-21 | — | — | CN | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-106794174-B | Compounds for the treatment of cancer | GTX公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-111253336-A | Compounds for the treatment of cancer | GTX公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-0619805-B1 | 5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS | PFIZER (US) | 2000-03-15 | — | — | EP | disclosed |
| CN-1045294-C | Indole derivatives | PFIZER (US) | 1999-09-29 | — | — | CN | disclosed |
| US-5639752-A | SEROTONIN AGONIST | PFIZER INC (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0619805-A1 | INDOLE DERIVATIVES | PFIZER HOSPITAL PRODUCTS, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993011106-A1 | INDOLE DERIVATIVES | PFIZER, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MAOB 2022/4885MAOA 2964/4885NPC1 1453/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MAOB 2022/4885MAOA 2964/4885NPC1 1453/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAOB 2022/4885MAOA 2964/4885NPC1 1453/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | MAOB 36/4885MAOA 19/4885NPC1 906/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAOB 2022/4885MAOA 2964/4885NPC1 1453/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MAOB 2022/4885MAOA 2964/4885NPC1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.